Capricor Therapeutics is trading 6.37% down now at $9.26 after Robbins Geller announced a September 28, 2026 lead-plaintiff deadline for a securities class action alleging violations involving Deramiocel disclosures.
- The lawsuit concerns earlier FDA-related clinical-data issues, including statistical-analysis-plan changes and questions about efficacy.
- The decline is occurring despite broader strength in equities and biotechnology, as legal overhang and profit-taking outweigh the earlier Piper Sandler upgrade and FDA-review optimism.